/
Respiratory
Asthma
147
Pipeline Programs↗
237
Active Trials↗
135
Companies Involved↗
Asthma is a highly competitive landscape with 147 programs across 135 companies. The most active players are Novartis, GSK, Guangdong Hengrui Pharmaceutical Co., Ltd. 24 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical79
Phase 15
Phase 239
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
115 of 122 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 122 classified programs, each share of the total. Modality classified for 95% of 147 pipeline programs.
Analysis
Trial Status
1,755
clinical trials
Completed1,208 · 69%
Recruiting133 · 8%
Terminated128 · 7%
Unknown status115 · 7%
Withdrawn64 · 4%
Active, not recruiting53 · 3%
Other54 · 3%
Clinical Trials
Trial Activity
1755 trials
Page 1 of 117
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)